GlassScriptPhysician profile
David James Arcella
NPI 1851652150
$17,664.56
in general payments reported to CMS, 2019-2025
29 companies · $903 in 2025
The $903 reported for 2025 was more than what 94% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,222 · 2020: $845 · 2021: $508 · 2022: $5,508 · 2023: $1,588 · 2024: $4,092 · 2025: $903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,625 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,610 · Travel and Lodging: $348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,624.72 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,610.00 |
| Travel and Lodging | $347.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,928.19 | 2019-2025 | Eterna, Proclaim, Axium |
| Medtronic USA, INC. | $3,644.50 | 2019-2020 | |
| Nevro Corp. | $2,898.69 | 2019-2024 | Vyrsa V1, Senza |
| Spinal Simplicity, LLC | $1,402.09 | 2022-2025 | Ha Minuteman G3-R |
| Medtronic, INC. | $1,345.51 | 2021-2024 | Synchromedii, Intellis Adaptivestim |
| Biodelivery Sciences International, INC. | $1,078.88 | 2019-2021 | |
| Mml US, INC. | $738.19 | 2023-2024 | Reactiv8 |
| Globus Medical, INC. | $327.89 | 2025 | Senza |
| Electronic Waveform Lab, INC. | $187.04 | 2019-2023 | |
| Boston Scientific Corporation | $185.59 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Saluda Medical Americas, INC. | $155.94 | 2023-2025 | Evoke Scs, Evoke |
| Grt US Holding, INC. | $150.29 | 2022 | |
| Collegium Pharmaceutical, INC. | $110.91 | 2019-2022 | |
| Si-Bone, INC. | $101.89 | 2019-2024 | |
| Curonix LLC | $72.45 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $41.76 | 2022-2025 | Sprint Pns System |
| Painteq LLC | $40.27 | 2023-2024 | Painteq |
| Assertio Therapeutics, INC. | $38.26 | 2019 | |
| Vertos Medical, INC. | $30.37 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $26.50 | 2024 | |
| Kaleo, INC. | $24.99 | 2019 | |
| Almatica Pharma LLC | $22.72 | 2021 | |
| Pacira Therapeutics, INC. | $22.68 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.60 | 2025 | Relistor |
| Forte Bio-Pharma LLC | $16.30 | 2022 | |
| Merck Sharp & Dohme LLC | $16.08 | 2024 | Bridion |
| Scilex Pharmaceuticals INC. | $14.09 | 2019 | |
| Zyla Life Sciences, INC. | $13.15 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Arcella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.